MANGALAM
Mangalam Drugs And Organics Limited
Mangalam Drugs And Organics Limited (MANGALAM) financial statements and selected valuation metrics through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
mangalamdrugs.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Mangalam Drugs and Organics manufactures bulk drugs (active pharmaceutical ingredients) at its factory in Vapi, Gujarat, and reports this as its single business segment.
Company snapshot
116thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
- ✓93% of operating profit came in as cash over the last three years — profits are backed by real cash.
- ✗Net margin is negative — the company is spending more than it earns right now.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 97 Cr | 102 Cr | 77 Cr | 80 Cr | 89 Cr | 73 Cr | 57 Cr | 50 Cr | 58 Cr | 67 Cr | 57 Cr |
| Operating expenses (approx.) | 90 Cr | 91 Cr | 68 Cr | 71 Cr | 80 Cr | 63 Cr | 62 Cr | 52 Cr | 60 Cr | 73 Cr | 56 Cr |
| EBITDA | 7 Cr | 12 Cr | 8 Cr | 9 Cr | 9 Cr | 10 Cr | -4 Cr | -3 Cr | -1 Cr | -6 Cr | 0.90 Cr |
| OPM % | 7.2% | 11.4% | 10.7% | 10.9% | 9.9% | 13.9% | -7.8% | -5.7% | -2.4% | -8.4% | 1.6% |
| Other income | 0.0019 Cr | 0.05 Cr | 0.02 Cr | 0.14 Cr | 0.14 Cr | 0.21 Cr | 0.0004 Cr | 0.03 Cr | 0.11 Cr | 0.09 Cr | 0.11 Cr |
| Interest | 3 Cr | 4 Cr | 4 Cr | 4 Cr | 3 Cr | 4 Cr | 4 Cr | 5 Cr | 4 Cr | 3 Cr | 4 Cr |
| Depreciation | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 5 Cr | 4 Cr | 5 Cr | 4 Cr | 5 Cr | 4 Cr |
| Profit before tax | 0.04 Cr | 4 Cr | 0.58 Cr | 1 Cr | 1 Cr | 2 Cr | -13 Cr | -12 Cr | -10 Cr | -13 Cr | -7 Cr |
| Tax % | -1091.1% | 10.1% | -359.2% | -124.2% | 5.9% | 96.4% | -6.2% | 41.1% | -0.0% | -1.1% | -13.2% |
| Net profit | 0.50 Cr | 4 Cr | 3 Cr | 3 Cr | 1 Cr | 0.06 Cr | -14 Cr | -7 Cr | -10 Cr | -13 Cr | -8 Cr |
| EPS (₹) | ₹0.31 | ₹2.23 | ₹1.70 | ₹1.70 | ₹0.81 | ₹0.04 | ₹-8.72 | ₹-4.64 | ₹-6.21 | ₹-8.48 | ₹-4.83 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 369 Cr | 318 Cr | 232 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 351 Cr | 282 Cr | 247 Cr | Sign in free for the trailing twelve months |
| EBITDA | 17 Cr | 36 Cr | -15 Cr | Sign in free for the trailing twelve months |
| OPM % | 4.7% | 11.3% | -6.4% | Sign in free for the trailing twelve months |
| Other income | 0.10 Cr | 0.50 Cr | 0.76 Cr | Sign in free for the trailing twelve months |
| Interest | 14 Cr | 15 Cr | 16 Cr | Sign in free for the trailing twelve months |
| Depreciation | 15 Cr | 17 Cr | 18 Cr | Sign in free for the trailing twelve months |
| Profit before tax | -11 Cr | 5 Cr | -49 Cr | Sign in free for the trailing twelve months |
| Tax % | 18.1% | -40.4% | 8.6% | Sign in free for the trailing twelve months |
| Net profit | -9 Cr | 7 Cr | -44 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹-5.73 | ₹4.25 | ₹-28.05 | Sign in free for the trailing twelve months |
| Dividend payout % | — | 0.0% | — | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 16 Cr | 16 Cr | 16 Cr |
| Reserves | 120 Cr | 133 Cr | 87 Cr |
| Borrowings | 88 Cr | 81 Cr | 105 Cr |
| Other liabilities | 110 Cr | 136 Cr | 106 Cr |
| Total liabilities | 333 Cr | 366 Cr | 315 Cr |
| Fixed assets (net) | 104 Cr | 134 Cr | 116 Cr |
| CWIP | 0 Cr | 0 Cr | 0 Cr |
| Investments | 0.0044 Cr | 0.0044 Cr | 0.0044 Cr |
| Loans & advances | 1 Cr | 1 Cr | 0.05 Cr |
| Inventories | 124 Cr | 139 Cr | 103 Cr |
| Trade receivables | 28 Cr | 39 Cr | 40 Cr |
| Cash & bank | 0.90 Cr | 3 Cr | 0.70 Cr |
| Other assets | 76 Cr | 51 Cr | 55 Cr |
| Total assets | 333 Cr | 366 Cr | 315 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | -11 Cr | 43 Cr | 4 Cr |
| Cash from investing | 0 Cr | -19 Cr | -12 Cr |
| Cash from financing | 0 Cr | -22 Cr | 6 Cr |
| Net cash flow | -11 Cr | 1 Cr | -2 Cr |
| Free cash flow (OCF − Capex) | -11 Cr | 22 Cr | -8 Cr |
Ratios
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 1.3% | 8.6% | -15.5% |
| ROE % | -6.7% | 4.5% | -43.1% |
| Debtor days | 28 | 45 | 63 |
| Inventory days | 201 | 296 | 300 |
| Days payable | 107 | 195 | 221 |
| Cash conversion cycle | 121 | 146 | 142 |
| OCF / EBITDA % | -63.7% | 118.9% | — |
| OCF / EBITDA % (3 years) | — | — | 93.2% |
| Debt / equity | 0.65 | 0.54 | 1.02 |
| Current ratio | 1.07 | 1.04 | 0.79 |
| Net debt / EBITDA | 5.00 | 2.19 | — |